Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy

British Journal of Cancer

Volumn 100, Issue 3, 2009, Pages 455-463

  Kiserud, C E ^a   Fossa A ^a   Bjoro T ^a   Holte, H ^a   Cvancarova, M ^a   Fossa S D ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Chemotherapy; Gonadal function; Male lymphoma survivors

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; HORMONE; IFOSFAMIDE; LUTEINIZING HORMONE; MELPHALAN; METHOTREXATE; MITOGUAZONE; PREDNISONE; PROCARBAZINE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEAM THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; ENDOCRINE FUNCTION; EXOCRINE SECRETION; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; GONAD FUNCTION; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NORWAY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TESTIS;

EID: 59649094063     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604892     Document Type: Article

References (31)

1. Abrahamsen AF, Hannisdal E, Nome O, Holte H, Hager B, Langholm R, Kvaloy S (1996) Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol 7: 145-150
2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92: 4241-4247
3. Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001) Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl 64: 14-20
4. Blystad AK, Holte H, Kvaloy S, Smeland E, Delabie J, Kvalheim G (2001a) High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant 28: 849-857
5. Blystad AK, Torlakovic E, Holte H, Kvaloy S, Lenschow E, Kvalheim G (2001b) CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy 3: 295-305
6. Botchan A, Hauser R, Gamzu R, Yogev L, Lessing JB, Paz G, Yavetz H (1997) Sperm quality in Hodgkin's disease versus non-Hodgkin's lymphoma. Hum Reprod 12: 73-76
7. Evensen SA, Brinch L, Tjonnfjord G, Stavem P, Wisloff F (1994) Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia. Br J Haematol 88: 88-93
8. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley Jr WF (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106: 354-361
9. Fitoussi O, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B (2000) Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol 11: 679-684
10. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, Snowden JA, Derogatis L, Shalet SM, Ross RJ (2007) Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab 92: 3476-3482
11. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5: 556-561
12. Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000) Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36: 1762-1768
13. Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF (1996) ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncol 35(Suppl 8): 73-80
14. Howell SJ, Radford JA, Adams JE, Shalet SM (2000) The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol (Oxf) 52: 609-616
15. Howell SJ, Radford JA, Ryder WD, Shalet SM (1999) Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 17: 1493-1498
16. Howell SJ, Shalet SM (2001) Testicular function following chemotherapy. Hum Reprod Update 7: 363-369
17. Huddart RA, Norman A (2003) Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy. Br J Cancer 89: 1143-1144
18. Kiserud CE, Fossa A, Holte H, Fossa SD (2007) Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 96: 1442-1449
19. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24: 2917-2931
20. Merk K, Idestrom K, Johansson B, Kimby E, Lindemalm C, Osby E, Bjorkholm M (1991) Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. Eur J Haematol 46: 33-37
21. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 62: 64-73
22. Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fossa SD (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44: 322-328
23. Rueffer U, Breuer K, Josting A, Lathan B, Sieber M, Manzke O, Grotenhermen FJ, Tesch H, Bredenfeld H, Koch P, Nisters-Backes H, Wolf J, Engert A, Diehl V (2001) Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 12: 1307-1311
24. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, Dorffel W, Zimmermann M, Mann G, Gadner H, Parwaresch R, Riehm H, Reiter A (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97: 3699-3706
25. Smeland S, Blystad AK, Kvaloy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrom J, Lauritzsen GF, Holte H (2004) Treatment of Burkitt's/ Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 15: 1072-1078
26. Svartberg J, Midtby M, Bonaa KH, Sundsfjord J, Joakimsen RM, Jorde R (2003) The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 149: 145-152
27. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001) High-dose therapy and autologous stem-cell transplantation vs conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19: 2927-2936
28. van der Kaaij MA, Heutte N, Le SN, Raemaekers JM, Simons AH, Carde P, Noordijk EM, Ferme C, Thomas J, Eghbali H, Kluin-Nelemans HC, Henry-Amar M (2007) Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25: 2825-2832
29. Viviani S, Ragni G, Santoro A, Perotti L, Caccamo E, Negretti E, Valagussa P, Bonadonna G (1991) Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 27: 1389-1392
30. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (1985) Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21: 601-605
31. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG (1982) The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 49: 418-422